I think most agree it's a tad underwhelming despite identified issues. Early stage sales momentum for a new technology in what is now a big market in dentistry (implants) you would expect to be quite large. I recently asked a young dentist whether they had heard of striate and they hadn't (it's a pretty significant practice doing implants for over a decade). In the end the next stage products should be more significant to OCC success going forward. Well funded but not expecting huge SP appreciation any time soon. GLTA
I think most agree it's a tad underwhelming despite identified...
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
39.5¢ |
Change
0.010(2.60%) |
Mkt cap ! $82.68M | |||
| Open | High | Low | Value | Volume |
| 38.5¢ | 39.5¢ | 38.5¢ | $28.61K | 74.11K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20000 | 38.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.5¢ | 5000 | 1 |
View Market Depth
| Last trade - 15.57pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
39.5¢ |
Change
0.010 ( 2.60 %) |
||||
| Open | High | Low | Volume | ||
| 39.5¢ | 39.5¢ | 39.5¢ | 2000 | ||
| Last updated 14.09pm 03/05/2024 ? | |||||
| OCC (ASX) Chart |